Patents by Inventor Thomas Daniel Aicher

Thomas Daniel Aicher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20230295119
    Abstract: Compounds having the structure of Formula (I) or pharmaceutically acceptable isomers, racemates, hydrates, solvates or salts thereof, where A, R1, R2a, R2b, R2c and R3 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on TYK2 to cause signal transduction inhibition, as well as to pharmaceutical compositions containing the same and to methods of their use and preparation.
    Type: Application
    Filed: April 14, 2021
    Publication date: September 21, 2023
    Inventors: Craig Alan Coburn, Chad Alan Van Huis, Thomas Daniel Aicher
  • (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20220388964
    Abstract: The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.
    Type: Application
    Filed: April 13, 2020
    Publication date: December 8, 2022
    Inventors: Savithri Ramurthy, Mark J. Mulvihill, Bradley Sherborne, Eric Talbot, Chris Thomson, Thomas Daniel Aicher, Fernando Padilla, Clarke B. Taylor, Peter L. Toogood
  • Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 11059796
    Abstract: The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: July 13, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS
    Publication number: 20210139484
    Abstract: The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 13, 2021
    Inventors: Thomas Daniel Aicher, Donald J. Skalitzky, Peter L. Toogood, Chad A. Vanhuis
  • ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
    Publication number: 20210061778
    Abstract: The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: March 9, 2020
    Publication date: March 4, 2021
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10611740
    Abstract: The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: April 7, 2020
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10421751
    Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 24, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
    Publication number: 20190135768
    Abstract: The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 9, 2019
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
    Patent number: 10112935
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 30, 2018
    Assignee: Lycera Corporation
    Inventors: Thomas Daniel Aicher, Fernando Padilla, Peter L. Toogood, Shoujun Chen
  • DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE
    Publication number: 20180111922
    Abstract: The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
    Type: Application
    Filed: May 5, 2016
    Publication date: April 26, 2018
    Inventors: Thomas Daniel Aicher, Clarke B. Taylor, Chad A. VanHuis
  • INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
    Publication number: 20180093978
    Abstract: The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.
    Type: Application
    Filed: February 26, 2016
    Publication date: April 5, 2018
    Inventors: Thomas Daniel Aicher, Fernando Padilla, Peter L. Toogood, Shoujun Chen
  • Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives
    Patent number: 9079890
    Abstract: Provided are intermediates having the formulas wherein R2, R3, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: July 14, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Indrani W. Gunawardana, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner, Eli M. Wallace
  • INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES
    Publication number: 20150057448
    Abstract: Provided are intermediates having the formulas wherein R2, R3, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.
    Type: Application
    Filed: September 23, 2014
    Publication date: February 26, 2015
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Indrani W. Gunawardana, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner, Eli M. Wallace
  • 2-aminopyridine analogs as glucokinase activators
    Patent number: 8883828
    Abstract: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: November 11, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Ronald Jay Hinklin, Ajay Singh
  • Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
    Patent number: 8853409
    Abstract: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: October 7, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Indrani W. Gunawardana, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner, Eli M. Wallace
  • PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
    Publication number: 20140256756
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X1, X2, X3, L, R3, R4, R5, R7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 11, 2014
    Inventors: Thomas Daniel Aicher, Josef Roland Benscik, Steven Armen Boyd, Kevin Ronald Condroski, Jay Bradford Fell, John Peter Fischer, Ronald Jay Hinklin, Scott Pratt, Ajay Singh, Timothy M. Turner
  • Piperidinyl-substituted lactams as GPR119 modulators
    Patent number: 8754226
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: June 17, 2014
    Assignee: Array BioPharma Inc.
    Inventors: Thomas Daniel Aicher, Josef Roland Bencsik, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Scott Alan Pratt, Ajay Singh, Timothy M. Turner, David A. Mareska, Steven Armen Boyd
  • N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20140088094
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Application
    Filed: November 8, 2011
    Publication date: March 27, 2014
    Applicants: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur Glenn Romero, Chad A. Van Huis, Thomas Daniel Aicher, Carl Kaub, Matthew N. Mattson, William David Thomas, Karin Ann Sttein, Erik Krogh-Jespersen, Zhan Wang
  • PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
    Publication number: 20130184257
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X1, X2, L, R3, R4, R5, R7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
    Type: Application
    Filed: September 15, 2011
    Publication date: July 18, 2013
    Inventors: Thomas Daniel Aicher, Josef R. Bencsik, Steven Armen Boyd, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Scott Alan Pratt
  • PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
    Publication number: 20130158009
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.
    Type: Application
    Filed: May 13, 2011
    Publication date: June 20, 2013
    Inventors: Thomas Daniel Aicher, Josef Roland Bencsik, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Scott Alan Pratt, Ajay Singh, Timothy M. Turner, Steven Armen Boyd